Survivor Spotlight: Erich & Jenn Djordjevic
By Mara Klecker Note: Erich passed away on September 28th, 2022, the same week his story ran in our newsletter.…
Blog - Melanoma360
09/06/2022
Survivor Spotlight: Erich & Jenn Djordjevic
By Mara Klecker Note: Erich passed away on September 28th, 2022, the same week his story ran in our newsletter.…
|
09/06/2022
Survivor Spotlight: Bev Johnson, Mucosal Melanoma Survivor
By Mara Klecker Bev Johnson figured the abnormal bleeding she was experiencing was a side effect of her IUD losing…
|
08/09/2022
The Trouble with Toxic Positivity With Whitney Goodman, LMFT, Author
When going through difficulty, many people turn to friends and family for support. But what happens when those people dismiss…
|
07/22/2022
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag
(reprint from Business Wire, published: July 22, 2022) Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody…
|
07/13/2022
2022: The State of Sunscreen in the U.S.
July is UV Safety Awareness Month, and with so much time spent outdoors, practicing sun safety should be top of…
07/13/2022
Sun Safety and Psychological Challenges For Melanoma Survivors
Many skin cancer survivors develop high anxiety regarding sun exposure and being outside, especially during summer. How can active coping…
|
07/12/2022
Parenting While Living With Melanoma
by Mara Klecker It’s natural and common to worry about how a parent’s cancer diagnosis and treatment is going to…
|
|
06/22/2022
Survivorship: Living Well with Melanoma
Cancer Survivorship begins the moment you learn of your diagnosis and continues long after treatment. And thanks to medical advances,…
|
06/22/2022
Steve Banks, Stage III Survivor, Doesn’t Let Melanoma Define His Life
by Mara Klecker Steve Banks doesn’t often bring up his melanoma diagnosis during a first date, though he’s always forthright…
|
06/06/2022
Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma
(reprint from Biospace, published: Jun 03, 2022) Immunocore announcesclinical trial collaboration with Sanofito evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2,in combination with KIMMTRAK® in patients with metastatic cutaneous…
|
Recent Posts
Jan. 21, 2025
Replimune Announces BLA Acceptance and Priority Review for RP1 for the Treatment in Advanced Melanoma
Jan. 14, 2025
Meaning-Centered Psychotherapy: Finding Purpose in the Face of Cancer
Jan. 09, 2025
What Inspires Leading Melanoma Researchers?
Dec. 30, 2024
Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients
Dec. 27, 2024